We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Blog

Hybridoma vs Phage Display for Monoclonal Antibody Production
Blog

This blog highlights the key advantages and drawbacks of hybridoma development and phage display for a monoclonal antibody production in order to help you determine the best method for your needs.

Read More

Supporting Drug Discovery with Cell-centered Models of the Immune System
Blog

Many biological processes, specifically the immune system, operate at a cellular level. CytoReason have harnessed this knowledge to build computational, high-resolution, mechanistic models for a range of diseases that enables better discovery and validation of drug targets.

Read More

Antibody Cascade Design Key to Customizing Success
Blog

We caught up with Abcam's Head of Custom Services, Jamie Campbell, who recently presented at the Protein & Antibody Engineering Summit, Europe. Jamie discusses the company’s approach to discovering antibodies – key reagents in drug discovery, in vitro diagnostics and therapeutics.

Read More

Deciphering RNA to Predict if a Patient Will Respond to a Targeted Drug
Blog

We recently spoke to Alif Saleh, CEO of Scipher Medicine to learn how RNA data from a patient’s blood sample can be used to determine the underlying molecular processes driving a disease, and establish how well a patient will respond to a particular therapy.

Read More

Tandem Mass Spectrometry: Rising to Challenges in Clinical Labs
Blog

Assay sensitivity and specificity continues to be a challenge in measuring hormones at low concentrations. Tandem mass spectrometry offers significant advantages - particularly in a clinical setting, where speed and sensitivity are required. Following SCIEX' launch of a new tandem mass spectrometry system, we spoke with Michael Jarvis, Product Manager at SCIEX, to find out more.

Read More

Combating Neurodegenerative and Age-related Diseases
Blog

We recently spoke to Karoly Nikolich, chairman and chief executive officer of Alkahest, a clinical-stage biotechnology company, to learn more about their approach to developing therapeutics for both neurodegenerative and age-related diseases.

Read More

Immunotherapy Response Prediction in Urothelial Cancer
Blog

While immunotherapy holds great promise for cancer treatment, challenges persist around limited response rate and severe immune-related adverse events. We caught up with Dr. Georg Lautscham, CEO of Protagen, to find out how the prediction of immunotherapy response can be improved for people with urothelial cancer.

Read More

Accelerating the Development of Liver Gene Medicines
Blog

Recent technology advancements have enabled the opportunity to increase the efficiency, efficacy and safety of gene and cell-based medicines for a multitude of genetic disorders. To date, a major challenge facing the field has been the ability to deliver therapeutic genes to affected cell types. In this blog, Sarah Haecker Meeks and Michael Roberts from Synpromics outline the ways in which gene medicines can be optimized to overcome this barrier.

Read More

The Changing Shape of Optofluidics R&D
Blog

Life science businesses are facing growing demand to keep pace in an era of fast-evolving technology. By recognizing the potential challenges, a growing number of companies are leveraging the resources and creativity of their suppliers. We took a look at the landscape of optofluidics R&D.

Read More

Developing Therapies to Fight Cancer and Autoimmune Diseases
Blog

We recently spoke to Alexis Peyroles, CEO at OSE Immunotherapeutics to hear more about the findings of their recent study, describing, for the first time ever, the in vivo MOA of interleukin 7 receptor alpha (IL-7Rα) monoclonal antibodies, suggesting therapeutic efficacy in controlling chronic inflammation.

Read More